MHNPC

Clinical trials for MHNPC explained in plain language.

Never miss a new study

Get alerted when new MHNPC trials appear

Sign up with your email to follow new studies for MHNPC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New combo therapy targets advanced prostate cancer in early trial

Disease control Not yet recruiting

This early-phase study tests a new drug called LC-K76 combined with standard hormone therapy in 40 men with metastatic hormone-sensitive prostate cancer. The main goal is to check safety and see if the drug helps lower PSA levels. Participants will take the drug for 24 weeks and …

Matched conditions: MHNPC

Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control

Last updated May 17, 2026 11:19 UTC

MHNPC

Get alerted when new MHNPC trials appear

New combo therapy targets advanced prostate cancer in early trial